- EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.
- You can view the full Merck Ratings Report.
Doug Kass shares his thoughts on biotech, and discusses the shape of things to come.
Here's how to trade seven of the most active stocks on the market this week.
Bristol-Myers Squibb suffers a setback in immunotherapy treatment for newly diagnosed lung cancer.